Terry Pirovolakis

Co-founder of CureSPG50 · Elpida Therapeutics

Terry Pirovolakis, co-founder of CureSPG50, confronted his child's SPG50 diagnosis in 2019. Through successful fundraising, he led groundbreaking research that treated three children within three years. Pirovolakis established Elpida Therapeutics, a corporation with a nonprofit approach, focusing on gene therapies for ultra-rare conditions. Collaborating with industry leaders, Elpida targets SPG50, CMT4J, and CLN7 and plans to address three additional diseases in 2025/2026, using profits to sustain its programs. Pirovolakis extends his impact by supporting foundations, providing Gene Therapy 101 classes, and collaborating, all centered on the goal of saving as many children as possible.

Is this you? Claim this profile →